KINETIC 2: An ongoing phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor
Objective: KINETIC 2 (NCT05173012) is an ongoing, phase 2b, randomized, double-blind, placebo-controlled, dose-response study that aims to evaluate the efficacy, safety, and tolerability of SAGE-324/BIIB124…Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor
Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research
Objective: To understand patient experience in essential tremor (ET), describe meaningful concepts related to treatment benefit, and compare concepts to existing clinical outcome assessments (COAs).…Weighing tremor reduction and side effects: Impact of efficacy and safety outcomes on patient satisfaction at 6 months in MR-guided focused ultrasound thalamotomy for tremor treatment
Objective: To relate efficacy and safety outcomes to patient satisfaction at 6 months after MR-guided focused ultrasound (MRgFUS) thalamotomy in the ventral intermediate nucleus (VIM)…A single centre retrospective study of dual target deep brain stimulation for clinically complex essential and dystonic tremor – a 5-year follow up
Objective: Measure efficacy of dual target deep brain stimulation in pharmaco-refractory tremors. Background: Tremor is characterised by involuntary rhythmic movement present in one or more…Axial tremor response to tractography-defined focused ultrasound thalamotomy for essential tremor: a prospective study
Objective: To analyse the effects of unilateral magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy defined by 4-tract tractography on axial tremor at 6 months in patients…Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.
Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…Neuropsychological Outcomes After Bilateral Focused Ultrasound Thalamotomy within Essential Tremor
Objective: The objective of the study was to elucidate the neuropsychological outcomes in executive functioning for patients with essential tremor undergoing bilateral MRI guided Focused…Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects
Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…Comparing Change in Motor and ADL Rating Scales after DBS in Parkinson’s disease, Dystonia and Tremor
Objective: To assess the relationship between deep brain stimulation (DBS)-induced improvements on motor symptoms and activities of daily living (ADL) in a single-center cohort of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »